gainbot
BriefMoversScreensSectorsEarningsIPOsNewsDividends & splitsScreenerWatchlistLearn
NASDAQ · VIRHealthcareBiotechnology

Vir Biotechnology, Inc. Common Stock (VIR)

$11.77+4.90%
Close Nov 4, 2026 · split-adjusted
Nov 3, 2026$11.22▲ 100.36% in range
Nov 3, 2025Low $5.12 · High $11.93Nov 3, 2026
What changed · written from our data
As of Nov 4, 2026

Vir Biotechnology closed at $11.77 on Nov 4, up 4.90%, 1.3% below its 52-week closing high. Volume of 2.8M shares was 1.62× its 20-day average (above normal).

Split-adjusted performance: +1.5% over one month, +14.4% over six months, +110.2% over one year.

In the quarter ended Jun 30, 2026, revenue was $238.95M, up 19582.5% from a year earlier, with a net margin of 33.5%.

Short interest was 16.2M shares at the Oct 15 settlement, up 8.4% from the prior report (12.3% of float, 6.9 days to cover).

Market cap$1.99B169.2M shares
Revenue · quarter$238.9M+19582.5% YoY
Diluted EPS$0.47—
P/E · TTM—P/S 6.6×
Net margin33.5%Gross 100.0%
Dividend yieldNone
52-week range5.12 – 11.93−1.3% from high
Volume2.8M1.62× 20-day avg
Volatility · 60d52.3%Annualised
Short % of float12.3%6.9 days to cover
Net cash$532.7MCash $532.7M
Next earnings—Not scheduled
Split-adjusted performance
1W −1.3%1M +1.5%3M +34.3%6M +14.4%YTD +95.2%1Y +110.2%3Y +46.2%5Y −69.9%

Earnings reactions

History →

No reported quarters with price history yet.

Rank within Biotechnology

Percentile among 139 companies (100 = best)

6-month momentum76
Revenue growth99
Net margin90
Value (low P/E)—
Size78

Industry medians: 6-month return −19.2%, revenue growth +8.8%, net margin −312.9%, P/E 22.0×.

Short interest

Details →
Shares short16.2M+8.4% vs prior
Days to cover6.9Settled Oct 15
% of float12.3%
Short vol. 10d63.3%of daily volume

Closest peers by size in Biotechnology

CompanyPriceToday6MRev. growthNet marginP/EMkt cap
VIRVir Biotechnology$11.77+4.90%+14.4%+19582.5%33.5%—$1.99B
REPLReplimune Group$20.69+0.19%+501.5%———$1.96BCompare
BCRXBioCryst Pharmaceuticals$8.24−3.85%−6.7%+33.6%35.9%—$2.11BCompare
COAGHemab Therapeutics Holdings$45.09+4.62%————$2.11BCompare
MAZEMaze Therapeutics$33.38+3.50%+26.1%———$1.85BCompare
NVAXNovavax$10.65+10.02%+13.8%−76.3%−94.2%—$1.76BCompare
RXRXRecursion Pharmaceuticals$3.88+5.43%+13.1%+258.5%−641.6%—$2.32BCompare
VCELVericel$45.48+10.68%+23.7%+22.5%2.8%96.2$2.33BCompare
ADMAADMA Biologics$10.48−5.67%+4.0%+2.0%30.4%13.9$2.35BCompare

News about Vir Biotechnology

All news →
Can Gilead's Deal With VIR Boost Its Oncology Pipeline and Growth?Zacks Investment Research · Oct 15, 2026▲ PositiveWhy a Biotech Fund Opened a New $6 Million Position in Vir Amid a 99% Stock RallyThe Motley Fool · May 23, 2026▲ PositiveVir Biotechnology (VIR) CEO Sells 73,000 Shares for $664,000The Motley Fool · Apr 12, 2026▲ Positive

Quick answers

What does Vir Biotechnology do?
Vir Biotechnology Inc is a clinical-stage biopharmaceutical company focused on powering the immune system by discovering and developing medicines for serious infectious diseases and cancer. The company uses its capabilities in antibody discovery and engineering, coupled with its proprietary AI engine dAIsY system, and the PRO-XTEN masking platform, to quickly and effectively discover and optimize potential new medicines.
What is VIR's market cap?
$1.99B, based on the Nov 4 close of $11.77.
Does Vir Biotechnology pay a dividend?
No regular cash dividend has been paid in the last year.
How much of VIR is sold short?
16.2M shares, 12.3% of float, as of Oct 15, 2026.
What sector is VIR in?
Healthcare, in the Biotechnology industry.

About Vir Biotechnology

Vir Biotechnology Inc is a clinical-stage biopharmaceutical company focused on powering the immune system by discovering and developing medicines for serious infectious diseases and cancer. The company uses its capabilities in antibody discovery and engineering, coupled with its proprietary AI engine dAIsY system, and the PRO-XTEN masking platform, to quickly and effectively discover and optimize potential new medicines. Its clinical development pipeline consists of investigational therapies like Tobevibart + elebsiran targeting the hepatitis delta virus (HDV), preclinical antibody candidates targeting HIV, and VIR-5500, VIR-5818, VIR-5525, and 7 PRO-XTEN programs targeting multiple solid tumors. Currently, the company generates revenue mainly by issuing license rights and through grants.

HQ: San Francisco, CA367 employeesListed Oct 11, 2019vir.bio

Sources: Massive / Polygon daily aggregates (split-adjusted) · SEC filings via Massive · FINRA settlements via Massive · Financial Modeling Prep. Figures are dated where shown; research is informational, not investment advice. Methodology